FERRING

History

Year	Detail
1950	Dr. Frederik Paulsen and Eva Frandsen established Nordiske Hormonlaboratorie, which focused on hormones, chemical and physiological research, and their application in medicines.
1954	Frederik Paulsen changed the company name from Nordiske Hormonlaboratorie to Ferring.
1956	Ferring moved from its rented location to its first self-owned factory in Malmö.
1961	Ferring expanded its business with the industry-scale production of synthetic peptide hormones vasopressin and oxytocin across the pharmaceutical industry.
1972	Ferring launched MINIRIN, an anti-diuretic hormone used to treat diabetes insipidus, nocturnal enuresis, and bedwetting.
1973	The company established its first production site in Kiel, Germany.
1990	Ferring opened its new subsidiaries in Eastern and Western Europe, South America, Asia, South Africa, and the Middle East.
1993	Ferring introduced its first product, MENOGON, in the area of infertility, to treat infertile couples.
2000	Ferring launched TRACTOCILE (atosiban), a new chemical entity manufactured by Ferring’s researchers to treat pre-term (premature) labor.
2011	Ferring acquired Cytokine PharmaSciences Inc. (CPSI) and its subsidiary, Controlled Therapeutics Scotland (CTS), and formed Ferring Controlled Therapeutics to continue its manufacturing activities in Scotland.
2018	Ferring acquired Rebiotix Inc., bringing together two advanced healthcare companies that share a commitment to exploring and understanding the human microbiome to develop new patient solutions.